Astra Zeneca U.k. Limited

Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron

Xentech Sas

Alba Llop Guevara

Mark J O'Connor

Cristina Cruz Zambrano

Judith Balmaña Gelpi

Marta Castroviejo Bermejo

Violeta Serra Elizalde

Gemma Nicole Jones

The invention provides a method allowing to determine whether a subject diagnosed with cancer is sensitive or resistant to an anti-cancer treatment, based on the level of cells with RAD51 foci in a sample containing tumor cells isolated from said subject, wherein the subject has not received at 24 hours prior to the isolation of the sample, a chemotherapy selected from the group consisting of AC, FEC, ECF and navelbine/epirubicin, and wherein the sample has not been treated with a method that induces DNA damage before determining the level of cells with RAD51 foci.

Methods based on the detection of RAD51 foci in tumor cells

Growing community of inventors

Barcelona, Spain

Alba Llop Guevara